-
Barclays Downgrades Chimerix Following Lowered Expectations
Tuesday, February 23, 2016 - 9:07am | 276Read More...Shares of Chimerix Inc (NASDAQ: CMRX) have plunged more than 40 percent on Monday. Barclays’ Geoff Meacham has downgraded the rating on the company from Overweight to Equal-Weight, while lowering the price target from $12 to $6. Following the release of full data from the SUPPRESS...
-
Barclays Prefers Biogen Over Celgene Heading Into Q4 Results
Friday, January 22, 2016 - 9:44am | 407Read More...Biogen Inc (NASDAQ: BIIB) shares have lost 12 percent since December 22, while shares of Celgene Corporation (NASDAQ: CELG) are down 5 percent. Barclays’ Geoff Meacham maintained an Overweight rating for Biogen, with a price target of $420, while reiterating an Equal-weight rating for...
-
Here's What Wall Street Thinks Of Chimerix After The Crash
Tuesday, December 29, 2015 - 11:12am | 357Read More...Chimerix Inc (NASDAQ: CMRX) shares were crushed on Monday, as the stock fell more than 80 percent following news that its brincidofovir SUPPRESS study fell short of endpoint expectations in the prevention of cytomegalovirus (CMV) infection. After the big fall, is it time to stick a fork in Chimerix...
-
Barclays Stays Overweight On Chimerix, Cuts Price Target By $53
Tuesday, December 29, 2015 - 9:13am | 217Read More...Shares of Chimerix Inc (NASDAQ: CMRX) dropped 81 percent this week, dropping almost to their 52-week low at $6.62. Barclays’ Geoff Meacham has maintained an Overweight rating on the company, while lowering the price target from $65 to $12. The company announced that its...
-
Barclays' Biopharmaceuticals Blueprint For 2016
Tuesday, December 1, 2015 - 12:54pm | 599Read More...Geoff Meacham of Barclays initiated coverage of six names within the "newly combined" U.S. Biopharmaceuticals sector. Meacham noted he is "positive" on the fundamentals and the "pipeline-driven evolution into a more specialty therapeutic areas." However, the...
-
J&J's 'Steady Cash Flow Is Key,' Barclays Upgrades To Overweight
Tuesday, December 1, 2015 - 9:26am | 349Read More...The share price of Johnson & Johnson (NYSE: JNJ) has appreciated 7.73 percent over the past three months, from $92.08 on September 1. Barclays’ Geoff Meacham has initiated coverage of the company with an Overweight rating and price target of $115. Meacham believes that it would be more...
-
Pfizer Is At A 'Strategic Crossroads'
Tuesday, December 1, 2015 - 9:09am | 348Read More...Shares of Pfizer Inc (NYSE: PFE) were volatile in 2015 and are up 5 percent year-to-date. Barclays’ Geoff Meacham assumed coverage of the company with an Equal-Weight rating and a price target of $34. Although the company has returned to modest growth in 2015, it is at a strategic...
-
Barclays On Merck: Too Much Underlying Value To Ignore
Tuesday, December 1, 2015 - 8:36am | 335Read More...Merck & Co., Inc. (NYSE: MRK) shares are down 13 percent in the last six months, having plunged in August and September and declining steadily in November. Barclays’ Geoff Meacham assumed coverage of the company with an Overweight rating and a price target of $66. Following the...
-
Vertex Pharma's Orkambi Gives It Huge Potential, Says Barclays
Monday, September 14, 2015 - 10:18am | 271Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are up 13 percent year-to-date, although never breaching the $140 mark before August. Barclays’ Geoff Meacham upgraded the rating for the company from Equal Weight to Overweight, while raising the price target from $120 to $150...
-
Not So Fast, Alexion Investors
Monday, September 14, 2015 - 9:01am | 248Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have declined by almost 9 percent in the last month. Barclays’ Geoff Meacham has downgraded the rating on Alexion from Overweight to Equal-Weight, while lowering the price target from $220 to $205. Following the delays in the...
-
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Wednesday, July 29, 2015 - 10:34am | 483Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...
-
Celgene-Receptos: How Wall Street Is Reacting
Wednesday, July 15, 2015 - 8:25am | 542Read More...Shares of Receptos Inc (NASDAQ: RCPT) were trading higher by more than 10 percent during Wednesday's pre-market session after it received an acquisition offer on Tuesday by Celgene Corporation (NASDAQ: CELG) for $232 per share, valuing the entire transaction at $7.2 billion. Several of Wall...
-
Barclays: BioMarin Is A Buy, Sees $150/Share
Friday, June 5, 2015 - 7:26am | 210Read More...In a report published Friday, Barclays analyst Geoff Meacham initiated coverage of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with an Overweight rating and $150 price target. The company has been witnessing robust P&L momentum and the analyst expects BioMarin to see large pipeline...
-
Barclays Raises Biogen Forecasts After Physician Survey
Wednesday, April 1, 2015 - 9:20am | 162Read More...Barclays on Wednesday issued a report highlighting Biogen Inc (NASDAQ: BIIB) after they conducted a global multiple sclerosis (MS) survey of 49 neurologists. Barclays rates Biogen as Overweight with a $500 price target. Analyst Geoff Meacham wrote, "Overall, our survey implies upside to near-term...
-
Barclays Expands Coverage To 7 New Biotech Stocks
Wednesday, March 4, 2015 - 12:29pm | 496Read More...Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm's thesis was that...
